



KEY HIGHLIGHTS



Well diversified mid-to-late stage pipeline with first-in-class drug candidates



A highly experienced management team with extensive expertise in metabolic drug development



Strong global partnerships secured for the most advanced clinical program, Imeglimin



Two differentiated programs for NASH (PXL770 / PXL065), a large and growing disease worldwide



Cash and cash equivalents as of June 30, 2020 were EUR 46.0 million (USD 51.5 million); cash runway into 2022

CONTACTS

- Corporate headquarters in Lyon, France
- Poxel also has subsidiaries in Tokyo, Japan, and in the Boston, Massachusetts area

Thomas Kuhn

CEO and Co-founder

Anne Renevot

Chief Financial Officer

Jonae Barnes

Investor Relations, Corporate Communications & Public Relations
jonae.barnes@poxelpharma.com

Aurélie Bozza

Investor Relations & Communication
aurelie.bozza@poxelpharma.com

NewCap

Investor Relations and Public Relations – France
poxel@newcap.eu

ABOUT POXEL

Founded in 2009 as a spin out of Merck Serono, Poxel is a **dynamic biopharmaceutical company** that uses its extensive expertise in developing **innovative drugs for metabolic diseases**, with a focus on **type 2 diabetes** and **non-alcoholic steatohepatitis (NASH)**. In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities.

Imeglimin, Poxel's first-in-class lead drug candidate targeting mitochondrial dysfunction. Working together with Poxel's partner, **Sumitomo Dainippon Pharma**, the Imeglimin Phase 3 Trials of **Imeglimin for Efficacy and Safety (TIMES)** program for the treatment of type 2 diabetes in Japan met its endpoints and objectives. A Japanese New Drug Application (J-NDA) is under review and product launch is targeted for 2021.





Poxel also has a partnership with **Roivant Sciences** for Imeglimin's development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe.

PXL770, Poxel's first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, was observed in a PK/PD trial to be safe and well-tolerated and demonstrated target engagement and efficacy signals. Efficacy and safety results from the Phase 2a study for the treatment of NASH are anticipated late Q3 2020.

PXL065, Poxel's mitochondrial pyruvate carrier (MPC) inhibitor, is advancing into a Phase 2 clinical trial for the treatment of NASH; initiation anticipated 2H 2020 (timing contingent on safe and stable environment due to COVID-19).

Poxel also has additional earlier-stage programs from its AMPK activator and deuterated TZD platforms targeting chronic and rare metabolic diseases.

A MID-TO-LATE STAGE FIRST-IN-CLASS METABOLIC PIPELINE

	Indication	MOA	Discovery/PC	PH 1	PH 2	PH 3	NDA review	Partner/ Rights
Type 2 Diabetes								
Imeglimin Japan / Asia*	Type 2 Diabetes (T2D)	MRC Modulator						
Imeglimin US / EU / Other**	T2D patients with CKD stages 3b/4	MRC Modulator						ROIVANT SCIENCES
NASH								
PXL770	NASH	Direct AMPK Activator						 POXEL
PXL065	NASH	MPC Inhibitor						 POXEL
PXL007 (EYP001)	Hepatitis B / NASH	FXR Agonist						ENYO PHARMA
Other Chronic and Rare Metabolic Indications								
Next-Gen AMPK	Adreno-leukodystrophy	Direct AMPK Activator						 POXEL
Next-Gen D-TZD	Chronic Kidney Diseases Undisclosed	MPC Inhibitor						

LEAD PROGRAMS

Imeglimin: orally-available drug candidate for the treatment of type 2 diabetes. It has a unique mechanism of action targeting mitochondrial dysfunction, enabling it to simultaneously target all three key organs of diabetes, including the pancreas, muscles and the liver. It has an extensive and consistent data package with 25 clinical studies in over 2,500 subjects and has been shown to have robust efficacy both alone and in combination with other drugs currently on the market. Imeglimin has also been shown to be well tolerated and to have a safety profile similar to placebo.

PXL770: orally available first-in-class product targeting adenosine monophosphate-activated protein kinase (AMPK). Through its unique mechanism of action that directly activates AMPK, PXL770 acts on a very important biological target. This target, which plays a key role as a master regulator of cellular energy, has the potential to treat several chronic and rare metabolic diseases, including diseases that affect the liver, such as NASH.

PXL065: (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is advancing into a Phase 2 clinical trial. Based upon preclinical and Phase 1a results, PXL065 is expected to exhibit a better therapeutic profile than pioglitazone for NASH, including efficacy with reduced side effects, such as those associated with the activation of gamma receptors activated by peroxisome proliferators (PPAR-γ) (weight gain, fractures and fluid retention).



Due to COVID-19, Poxel is monitoring all developments that might impact the timelines for achievement of our corporate objectives and we will continue to update you as needed.

TWO STRATEGIC PARTNERSHIPS FOR IMEGLIMIN



Sumitomo Dainippon Pharma

Strategic partnership with **Sumitomo Dainippon Pharma** signed in October 2017 for: Japan, China, South Korea, Taiwan, Indonesia, Vietnam, Thailand, Malaysia, The Philippines, Singapore, Republic of the Union of Myanmar, Kingdom of Cambodia, and Lao People's Democratic Republic.



Partnership with **Roivant Sciences**, signed in February 2018 for the U.S., Europe, and in all the other countries not covered in the Sumitomo Dainippon Pharma agreement.

- Partnerships cover global diabetes markets
- Potential of up to \$857M (~€705M*) in development and regulatory milestones, and sales-based payments
- Escalating double-digit royalties on net sales
- **Imeglimin Japanese New Drug Application (J-NDA) is under review**
 - Positive results from TIMES 1, TIMES 2 and TIMES 3
 - J-NDA under review by Pharmaceuticals and Medical Devices Agency (PMDA)
 - Product launch targeted in 2021 in Japan
- **Preparation for Phase 3 program in the U.S. and Europe**
 - Positive results from the PK/PD study in type 2 diabetes patients with chronic kidney disease (CKD) stages 3b/4
 - Metavant, Roivant's subsidiary dedicated to metabolic diseases, met with FDA in Q1 2020 to discuss Phase 3 program in type 2 diabetes patients with CKD stages 3b/4; discussions continue in 2H 2020 to finalize Phase 3 plan
- Phases 3 fully funded by Sumitomo in Japan, and by Roivant in the U.S. and Europe

* Converted at the exchange rate at the date of the agreement

NEAR-TERM MILESTONES EXPECTED TO DRIVE VALUE

IMEGLIMIN

2020

- Metavant discussions with FDA for Phase 3 program in T2D patients with CKD stages 3b/4
- Data presentations at EASD and JDS
- Imeglimin data published

2021

- Imeglimin **target launch** in Japan

PXL770

2H 20 2020

- **Ph 2a proof-of-concept** data results in NASH late Q3 2020
- Data presentations at EASD, AASLD and NASH Summit
- PXL770 data published

PXL065

2H 2020

- Initiation of a **Ph 2 program in NASH** (timing contingent on safe and stable environment due to COVID-19)
- AASLD presentation
- PXL065 data published

PREVALENCE

Prevalence of type 2 diabetes

In 2017, 425 million people aged 20 to 79 years old worldwide were suffering from diabetes, with over 90% from type 2 diabetes (International Diabetes Federation)

Prevalence of NASH

Today, approximately 40 million people are affected by NASH in the U.S., France, Germany, Italy, Spain, the United Kingdom and Japan (Decision Resources)



SHAREHOLDER TOOLS

If you wish to receive upcoming press releases from POXEL via email, simply send your **surname, name** and **email address** to poxel@newcap.eu

POXEL ON THE STOCK EXCHANGE

Market	Euronext Paris since February 2015
Ticker	POXEL
ISIN	FR0012432516
Market cap.	€188 million*
Number of shares	28,471,523**
Share price	€6.64*
52 week trading range	€4.61 – €13.80

*as of August 3 2020, **as of June 30, 2020

SHAREHOLDER STRUCTURE AS OF JUNE, 2020

